The Enterprise Value as of December 2024 (TTM) for ImmunityBio, Inc. (IBRX) is 2.55B

According to ImmunityBio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.55B. This represents a change of -38.98% compared to the average of 4.18B of the last 4 quarters.

ImmunityBio, Inc. (IBRX) Historical Enterprise Value (quarterly & annually)

How has IBRX Enterprise Value performed in the past?

The mean historical Enterprise Value of ImmunityBio, Inc. over the last ten years is 2.81B. The current 2.55B Enterprise Value has changed 8.97% with respect to the historical average. Over the past ten years (40 quarters), IBRX's Enterprise Value was at its highest in in the June 2015 quarter at 10.54B. The Enterprise Value was at its lowest in in the December 2014 quarter at -58839000.00.

ImmunityBio, Inc. (IBRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of ImmunityBio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmunityBio, Inc. (IBRX) Average Enterprise Value

How has IBRX Enterprise Value performed in the past?

The current Enterprise Value of ImmunityBio, Inc. (IBRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

ImmunityBio, Inc. (IBRX) Enterprise Value vs. Peers

How is IBRX’s Enterprise Value compared to its peers?

ImmunityBio, Inc.’s Enterprise Value is less than BioLineRx Ltd. (0), greater than Ardelyx, Inc. (45.15M), greater than Lexicon Pharmaceuticals, Inc. (1.18B), greater than Seres Therapeutics, Inc. (334.19M), greater than eFFECTOR Therapeutics, Inc. (191.53M), greater than Protalix BioTherapeutics, Inc. (4.74M), greater than PDS Biotechnology Corporation (107.55M), greater than aTyr Pharma, Inc. (36.48M), greater than Elevation Oncology, Inc. (138.44M), greater than CureVac N.V. (16.17M), greater than Reata Pharmaceuticals, Inc. (137.92M), less than Krystal Biotech, Inc. (6.64B), less than Vir Biotechnology, Inc. (4.16B), greater than Propanc Biopharma, Inc. (873.99M), greater than Viking Therapeutics, Inc. (1.33M), less than TG Therapeutics, Inc. (4.66B), less than X4 Pharmaceuticals, Inc. (5.06B), greater than Madrigal Pharmaceuticals, Inc. (82.27M), less than null (6.68B),

Build a custom stock screener for ImmunityBio, Inc. (IBRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunityBio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmunityBio, Inc. (IBRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmunityBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.